Cura Therapeutics

Executive Summary

Cura Therapeutics is a San Diego-based biotechnology company pioneering next-generation multimodal immunotherapies aimed at treating metastatic cancers and age-associated diseases. Founded in 2018, the company is developing CT101, a recombinant protein designed to simultaneously engage immunostimulatory, anti-fibrotic, and anti-senescence activities, thereby addressing multiple hallmarks of aging and cancer. This novel approach seeks to improve healthspan and longevity by combining tumor-fighting properties with tissue regeneration and immune rejuvenation. As a private firm, Cura Therapeutics operates with a focus on preclinical and early clinical development, leveraging its proprietary platform to create therapies that target fundamental disease mechanisms. The company's strategy positions it at the intersection of oncology and geroscience, a rapidly growing field attracting significant investor interest. With no publicly disclosed funding rounds or partnerships to date, Cura remains a relatively early-stage venture, yet its scientific premise holds promise for addressing large unmet needs in both cancer and aging-related conditions. The success of CT101 in preclinical models and its progression into clinical trials will be critical for the company's valuation and future financing opportunities.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data for CT101 in Age-Associated Disease Models65% success
• H1 2027IND Filing for CT101 in Metastatic Cancer Indication50% success
• 2026Partnership or Licensing Deal for CT101 Platform35% success